

DAFTAR PUSTAKA

- Amirudin R. 2010. Fisiologi dan Biokimia Hati. Dalam: Sudoyo, Aru W, Setiyohadi B, Alwi I, Marcellus S.K, Setiati S, *Buku Ajar Ilmu Penyakit Dalam*, Edisi Kelima Jilid Satu, Interna Publishing, Jakarta.
- Anonim. 2014. *Micromedex Drug Information*, USA, Truven Health Analytics.
- Asdie AH, Wiyono P, Rahardjo P, Triwibowo, Marcham SN, Danawati W. 2012. *Harrison Prinsip-prinsip Ilmu Penyakit Dalam*, Edisi ke-13, EGC, Jakarta, hlm.1638-63.
- Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. 2008. *Laporan Riset Kesehatan Dasar Tahun 2007*, Departemen Kesehatan Republik Indonesia, Jakarta.
- Baranova A, Lal P, Birerdinc A, Younossi ZM. 2011. Non-Invasive Markers for Hepatic Fibrosis. *BioMed Central Gastroenterology*, 11:91
- Bataller R, Brenner DA. 2005. Liver Fibrosis. *The Journal of Clinical Investigation*, 115 (2): 209-218.
- Beddosa P, Poynard T. 1996. An Algorithm for The Grading of Activity in Chronic Hepatitis C. The METAVIR Cooperative study Group. *Hepatology*. 24 ; 289 – 93.
- Bigoniya P, Singh C.S, Shukla A. 2009. A Comprehensive Review of Different Liver Toxicants Used in Experimental Pharmacology, International Journal of Pharmaceutical Sciences and Drug Research, 1(3): 124-135.
- Black JM, Hawks JH. 2009. *Medical Surgical Nursing: Clinical Management for Positive Outcomes*, 8th edition, Elsevier Saunders, USA.

- Carey, E., Carey, W. D., 2010. *Noninvasive Tests for Liver Disease, Fibrosis, and Cirrhosis : Is Liver Biopsy Obsolete*. Cleveland Clinic Journal of Medicine, 77(8):519-527
- Castillo AL, Pineda FP, Carnedas EO, Avilla FS, Vorackova FV, 2008. AST to Platelet Ratio Index (APRI) For The Non Invasive Evaluation Of Liver Fibrosis, *Annals of Hepatology*, 7(4): 350-357.
- Centers for Disease Control and Prevention (CDC). 2010. *Hepatitis B General Information*, Department of Health and Human Services.
- Ching SH, Chia C, Pin C, Hans H. 2010. Increased Incidence of Gastroesophageal Disease in Patients with Chronic Hepatitis B Virus Infection. *Hepatol Int*. 4:585-593.
- Desta Z, Wu GM, Morocho AM, Flockhart DA. 2002. *The Gastropokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6*. The American Society for Pharmacology and Experimental Therapeutics.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2008. *Pharmacotherapy: A Pathophysiologic Approach*, Edisi Ketujuh, The McGraw-Hill Companies, Inc., New York.
- Dourakis SP. 2008. *Drug Therapy in Liver Diseases*. Annals Of Gastroenterology, 21(4) : 215- 217.
- European Association for the Study of Liver. 2009. *EASL clinical practice guidelines: management of chronic hepatitis*, J Hepatol,50:227-242.
- Friedman S, Grendell J, McQuaid K. 2003. Current diagnosis and treatment in gastroenterology, edisi ke-2, London: McGraw-Hill.
- Frith J, Jones D, Newton, JL. 2009. *Chronic liver disease in an ageing population*, Age and Ageing, 38: 11-18.
- Giannini EG, Testa R, Savarino V. 2005. *Liver enzyme alteration: a guide for clinicians* , Canadian Medical Association Journal, 172 (3): 367-379.
- Gonzalez HM, Romero EM, Peregrina AA et al. 2003. *CYP2C19- and CYP3A4-dependent omeprazole metabolism in west Mexicans*. J Clin Pharmacol 43:1211-1215

- Guha IN, Rosenberg WM. 2008. *Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and other Modalities*, Clinics In Liver Disease, 12: 883-900.
- Gupta NK, Lewis JH. 2008. *Review article: the use of potentially hepatotoxic drugs in patients with liver disease*, *Alimentary Pharmacology & Therapeutics*, 28:1021-1041.
- Guyton AC, Hall JE, 2008. *Buku Ajar Fisiologi Kedokteran*, Edisi 11, EGC Jakarta.
- Hadi S. 2002. *Gastroenterologi*, Penerbit Alumni Bandung, Bandung
- Hardjoeno H. 2007. *Tes enzimatik hati, Interpretasi Hasil Tes Laboratorium Diagnostik*, Edisi lima, Lembaga penerbitan Universitas Hasanuddin, 271 278.
- Herlianto B. 2015. *Perbandingan Efek Hepatoprotektif dari Ekstrak Silimarin dan Arcangelesia Flava terhadap Kerusakan Hepar yang diinduksi oleh Rifampicin, Isoniazide dan Pyrazinamide pada Tikus Wistar*. Karya Akhir. Tidak Diterbitkan. Fakultas Kedokteran Universitas Brawijaya, Malang.
- Iman Supandiman. 2001. *Anemia sideroblastik*. Buku ajar ilmu penyakit dalam. Edisi 3. Jakarta. FKUI. p 512 - 4.
- Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. 2012. *Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis*, *BioMed Central Gastroenterology*, 12:14.
- Johnson DA. 2013. *New Guidelines on GERD*, (http://gastroenterology.jwatch.org/issue_pdf/JG1305.pdf, diakses pada tanggal 11 Agustus 2016).
- Kumar V, Cotran RS, Robbins SL. 2012. *Buku ajar patologi Robbins*, edisi ke-7, EGC, Jakarta.
- Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. 2005. Comparison and Validation of Simple Noninvasive test for prediction of Fibrosis in Chronic Hepatitis C, *Hepatology*, 41: 1376-1382.

- Lacy CF, Lora LA, Morton PG, Leonard LL. 2009. *Drug Information Handbook 18th Edition*, North American, Lexi-Comp American Pharmacists Association.
- Lammert C, Einar B, Anna N, Naga C. Oral Medication with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events. *Hepatology*, 2010; 51: 615-620.
- Lee D. 2012. *Drug-Induced Liver Disease*, (Online), (http://www.medicinenet.com/drug_induced_liver_disease/article.htm, diakses 12 Agustus 2016).
- Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. 2008. *Retrospective Evaluation of Serum Markers APRI and AST/ALT for Assessing Liver Fibrosis and Cirrhosis in Chronic Hepatitis B and C Patients with Hepatocellular Carcinoma*, *Internal Medicine*, 47:569-575.
- Lindseth GN. 2006. *Gangguan Hati, Kandung Empedu, dan Pankreatitis. Patofisiologi, Konsep Klinis Proses-Proses Penyakit*, Edisi 6.
- Luntungan LZ, Fatimawali, Bodhi W. Studi Karakteristik dan Penggunaan Obat Pada Penderita Hepatitis B di Rumah Sakit Pemerintah Kota Manado Periode Januari 2011-Desember 2012. *Jurnal Ilmiah Farmasi-UNSRAT*, 2013, Vol. 2 (3).
- McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R, 2010. Performance of the AST to Platelet Ratio Index (APRI) as a Noninvasive Marker of Fibrosis in Pediatric Patients with Chronic Viral Hepatitis, *Journal of Pediatric Gastroenterology and Nutrition*, 50 (3): 344-346.
- Mustofa S, Kurniawaty E. 2013. *Manajemen gangguan saluran cerna panduan bagi dokter umum*, Anugrah Utama Raharja, Lampung.
- Navarro VJ, Senior JR. 2006. *Drug Related Hepatotoxicity. The New England Journal of Medicine*, 354;731-39.
- Pandit A, Sachdeva T, Bafna P. 2012. *Drug-Induced Hepatotoxicity: A Review*, *Journal of Applied Pharmaceutical Science*, 02(05), 233-43.

- Panggabean, EL. 2010. Karakteristik Penderita Hepatitis B Rawat Inap Di RSUD Rantau Prapat Kabupaten Labuhan Batu Tahun 2006-2009. Tugas Akhir. Tidak Diterbitkan, Fakultas Kesehatan Masyarakat Universitas Sumatra Utara, Medan.
- Parsian H, Alizadeh M, Yahyapour Y. 2013. *Clinical Application of Non Invasive Markers of Liver Fibrosis dalam Practical Management of Chronic Viral Hepatitis*, Iran, Intech.
- Price SA, Wilson LM. 2006, *Patofisiologi: Konsep Klinis Proses-Proses Penyakit*, Edisi Keenam Volume Satu, EGC Penerbit Buku Kedokteran, Jakarta.
- Ramasamy SK, Kusumbe AP, Adams RH. 2014. *Regulation of tissue morphogenesis by endothelial cell-derived signals*, *Trends in Cell Biology* 2: 1–10.
- Ramon B, Daud AB. Liver Fibrosis. *The Journal of Clinical Investigation* 2005;115:209-18.
- Schuppan D, Afdhal NH. 2008. *Liver Cirrhosis*. *The Lancet*, 371(9615):838-851.
- Sebastiani G, Alberti A. 2006. *Non Invasive Fibrosis Biomarkers Reduce But Not Substitute the Need for Liver Biopsy*. *Gastroenterol*; 12 : 3682-94
- Sembiring J., 2009. *Korelasi Kadar Thrombopoietin Serum dengan Fibrosis Hati pada Penderita Hepatitis Kronik*, Diss; 1-16
- Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, Jun SY, Park CK. 2008. *Aspartate Aminotransferase to Platelet Ratio Index (APRI) can Predict Liver Fibrosis in Chronic Hepatitis B*, *Digestive and Liver Disease*, 40: 267-274.
- Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME, Goral V. 2007. *Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a University Hospital in Turkey*. *Intervirology*;50:133-7.
- Sloane E. 2004. *Anatomi dan Fisiologi untuk Pemula*, EGC Penerbit Buku Kedokteran, Jakarta.

- Sonderup MW. 2006. *Drug Induced Liver Injury is a Significant Cause of Liver Disease, Including Chronic Liver, Drug Induced Liver Injuries*, 29(6).
- Stibbe KJM, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, Knegt RJ. 2011. *Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and hepatitis C patients*, Erasmus Journal of Medicine, 1 (2):7-13.
- Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata S, Setiati S. 2010. *Buku ajar ilmu penyakit dalam jilid 3*, edisi ke-5, Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Sweetman, SC. 2009. *Martindale: The Complete Drug Reference 36th Edition*, UK, Pharmaceutical Press.
- Tarigan P. 2001. *Buku Ajar Penyakit Dalam jilid 1 Ed. 3 Sirosis Hati*. Jakarta: Balai Penerbit FKUI.
- Tarigan I. 2013. Hubungan Derajat Fibrosis Hati dengan Skor APRI dibandingkan dengan Fibroscan pada Pasien Hepatitis B dan C Kronik. Tesis. Tidak Diterbitkan, Fakultas Kedokteran Universitas Sumatera Utara, Medan.
- Thedja MD. 2012. *Genetic diversity of hepatitis B virus in Indonesia: Epidemiological and clinical significance*, DIC Creative, Jakarta.
- Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok ASF. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*, 38:518.
- Walace K, Burt AD, Wirght MC. Liver Fibrosis. *Biochemical Journal*, 2008;411:1-8.
- World Health Organization. 2002. Hepatitis B. Tersedia dari: <http://www.who.int/>. Diakses pada tanggal 22 Desember 2015.
- Wu SD, Wang JY, Li L. 2010. *Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: A comparative study*. World J Gastroenterol, 16(4):501-507.
- Yeh S, Chen P. 2010. *Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones*. *Oncology*, 172-179.